ALSO NOTED: Galvus gets EU committee nod; Merck appoints Vanderbilt official to board;

> The European Committee for Medicinal Products gave its blessing to Novartis' new diabetes med Galvus, after the company revised prescribing information to minimize liver-safety problems. The drug will likely be available in Europe during the first half of 2008. Report

> Merck has appointed Dr. Harry Jacobson, vice chancellor for health affairs at Vanderbilt University, to its board of directors, effective Tuesday. Report

> Genzyme said the FDA has broadened the use of its thyroid cancer diagnostic tool Thyrogen to include identification of cancerous residue in patients who have had their thyroids removed. Release

And Finally... Patients who fail to respond to the ovarian cancer treatment Paclitaxel lack a specific protein, according to a new study. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.